AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00471809
Drug: Budesonide + Salmeterol + Azithromycin
RxNorm normalized name: salmeterol and budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04322318
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04322318
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02437318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of placebo tablets for oral use administered once daily
Trial: NCT00528970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
Trial: NCT00412373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for 6 weeks
Trial: NCT03669640
Drug: RO6889450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
Trial: NCT03669640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
Trial: NCT01186744
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
Trial: NCT01186744
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral BID
Trial: NCT01186744
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
Trial: NCT01186744
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral BID
Trial: NCT01031420
Drug: single arm dose dense MVAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
Trial: NCT05441878
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin arm for resuscitation fluid
Trial: NCT02454361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00547001
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
Trial: NCT03169738
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03169738
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03169738
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Trial: NCT00027833
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00027833
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00027833
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02279407
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to Omega-3 carboxylic acids (olive oil)
Trial: NCT02279407
Drug: Omega-3 carboxylic acids
RxNorm normalized name: omega-3 carboxylic acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g administered as 4 x 1 g capsules
Trial: NCT02279407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to dapagliflozin 10 mg
Trial: NCT01149954
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Trial: NCT00958438
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
Trial: NCT03430037
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00297882
Drug: 1. Artemether-Lumefantrine (AL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
Trial: NCT02118896
Drug: FK506E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02106793
Drug: Mitomicin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
Trial: NCT02328053
Drug: Topical anti-fungal therapy
RxNorm normalized name: miconazole nitrate Topical Cream [Anti-Fungal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical antifungal medications like natamycin eye drops and voriconazole eye drops
Trial: NCT02106793
Drug: Identical placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo solution
Trial: NCT00002634
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002634
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01563029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04316702
Drug: Cymbalta / Lyrica - Drug treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Two medications currently licensed for the treatment of FM in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg twice a day, at morning and at bedtime, while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning).
Trial: NCT03814421
Drug: intermittent (40mg as a bolus injection daily for 72hours)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
Trial: NCT00713830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Trial: NCT00713830
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
Trial: NCT03199924
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular injection of 75mg / 3ml of Diclofenac solution
Trial: NCT03992261
Drug: Halobetasol Topical Foam
RxNorm normalized name: halobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foam
Trial: NCT03229174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sugar pill)
Trial: NCT03642704
Drug: Reinforced preventive ARV therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the mother is HIV-1 or HIV 1/2 infected:~* zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~* nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight \< 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.
Trial: NCT01724619
Drug: [F-18] fluorinated dihydrotestosterone (FDHT)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01146886
Drug: Placebo to BI 135585
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
Trial: NCT00983255
Drug: TR-701 FA for injection, 200 mg/vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
Trial: NCT00866229
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg per day for 12 weeks
Trial: NCT00866229
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg per day
Trial: NCT03279393
Drug: fluorodeoxyglucose (FDG)-PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
Trial: NCT00983255
Drug: TR-701 FA tablets
RxNorm normalized name: Folic Acid Tablets
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TR-701 FA will be given once orally as a 200 mg tablet in Part C.
Trial: NCT01261780
Drug: Sham device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
Trial: NCT03123120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weeks treatment
Trial: NCT00663039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (plus a booster dose) drug probe study using intranasal placebo
Trial: NCT01402193
Drug: Pre-radiotherapy commencement of Arimidex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
Trial: NCT01402193
Drug: Post radiotherapy commencement of Arimidex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
Trial: NCT00108108
Drug: HCD122
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04525885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet administered orally BID
Trial: NCT00448110
Drug: Intravenous Diclofenac (DIC075V)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
Trial: NCT00448110
Drug: Intravenous Ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Ketorolac
Trial: NCT00448110
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03450330
Drug: AZD4205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
Trial: NCT00002680
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03005210
Drug: Magicbuvir Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
Trial: NCT04271488
Drug: Tasurgratinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasurgratinib oral tablet.
Trial: NCT04271488
Drug: Tasurgratinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasurgratinib oral capsule.
Trial: NCT00713765
Drug: AZD3480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 total doses of 40 mg, on days 1-18
Trial: NCT02890966
Drug: SHR4640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day1\~Day7:oral administration
Trial: NCT02890966
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day1\~Day7:oral administration
Trial: NCT01642615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole placebo-matching capsules
Trial: NCT04431674
Drug: Definity Suspension for Injection
RxNorm normalized name: Definity Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI-guided ultrasound-stimulated microbubble-treatment
Trial: NCT04323956
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04323956
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03497598
Drug: Lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
Trial: NCT00184951
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00667173
Drug: IDP-115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application for 12 weeks
Trial: NCT00667173
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application for 12 weeks
Trial: NCT03400956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally, coated tablet, once daily
Trial: NCT01409343
Drug: TrasGEX™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose.
Trial: NCT02206178
Drug: N-acetylcysteine combination with acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02206178
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03311828
Drug: Imaging Agent
RxNorm normalized name: NON-IMAGING AGENTS RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Copper 64Cu-DOTA-daratumumab IV
Trial: NCT02358356
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral capecitabine 750mg/m2 b.i.d.
Trial: NCT02819908
Drug: Imprimis Less Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
Trial: NCT01143740
Drug: RO5045337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally day 1-10 each 28-day cycle, 3 cycles
Trial: NCT03259620
Drug: CLS006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide Topical Gel
Trial: NCT03259620
Drug: CLS006 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Topical Gel
Trial: NCT02285062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00345969
Drug: Transdermal Testosterone gel (1%)
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
Trial: NCT02285062
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02285062
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02365623
Drug: Background Regimen (BR)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide \[PZA\], ethambutol \[EB, EMB\], streptomycin \[SM\], kanamycin \[KM, KAN\], enviomycin \[EVM\], ethionamide \[TH\], cycloserine \[CS\], para-aminosalicylic acid \[PAS\], amikacin \[AMK\], levofloxacin \[LVFX\] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
Trial: NCT01845623
Drug: QAB149 75 mg Concept 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAB149 delivered via the concept 1 device.
Trial: NCT01845623
Drug: QAB149 75 mg Epic Test Fixture
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAB149 delivered via the EPIC test fixture
Trial: NCT04008927
Drug: HCV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
Trial: NCT04097379
Drug: LRX712
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LRX712 intra-articular injections
Trial: NCT04097379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intra-articular injections
Trial: NCT03914326
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to be taken with water at the same time every morning in a fasting state
Trial: NCT02896621
Drug: Chlorthalidone plus amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
Trial: NCT01090895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
Trial: NCT02125734
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
Trial: NCT01190735
Drug: Caffeine alkaloid
RxNorm normalized name: belladonna alkaloids / caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed.
Trial: NCT02903095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00710762
Drug: BIBF1120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00710762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02631473
Drug: +/- 200mg NANO-Lopinavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID
Trial: NCT02631473
Drug: +/- 200mg ritonavir NORVIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID
Trial: NCT02631473
Drug: 400mg Sustiva
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04397770
Drug: SHR1210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Trial: NCT03131427
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care according to the updated national and/or international guidelines
Trial: NCT00002501
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes